Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Skye Bioscience ( (SKYE) ).
On February 24, 2025, Skye Bioscience, Inc.’s Board of Directors approved an Amended and Restated 2024 Inducement Equity Incentive Plan. This plan provides the Administrator with broader authority over equity awards in the event of a Change in Control, allowing for actions such as cancellation, substitution, or replacement with cash incentives, while maintaining most terms from the previous plan.
More about Skye Bioscience
Skye Bioscience, Inc. operates in the biotechnology industry, focusing on developing pharmaceutical products. The company is primarily engaged in creating innovative therapeutics and has a market focus on advancing treatments through its proprietary technologies.
YTD Price Performance: 1.40%
Average Trading Volume: 188,283
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $87.68M
For an in-depth examination of SKYE stock, go to TipRanks’ Stock Analysis page.